USFDA inspection finds these lapses at Zydus Lifesciences

In response to these violations, the USFDA has demanded a detailed remediation plan from Zydus.

286
USFDA Inspection
USFDA Inspection

Last Updated on December 21, 2024 by The Health Master

USFDA

Zydus Lifesciences has found itself in hot water after the US Food and Drug Administration inspection (USFDA inspection) followed by issuing a stern warning letter to the company.

The regulator cited multiple manufacturing lapses at the drugmaker’s plant in Gujarat.

Key Violations and Consequences:

  • Inadequate Contamination Investigations: The USFDA criticized Zydus for failing to thoroughly investigate contamination incidents at its Jarod-based plant. This included neglecting to examine all impacted batches, manufacturing equipment, and testing methods.
  • Cross-Contamination Events: The regulator found that the facility had experienced multiple cross-contamination events over a three-month period.
  • Glass Particulate Contamination: Zydus was also flagged for failing to adequately investigate and address glass particulate contamination in batches of Cyanocobalamin Injection.
  • Substandard Aseptic Practices: The USFDA noted that the company’s procedures for preventing microbiological contamination were inadequate, including the validation of aseptic and sterilization processes.

USFDA Demands Corrective Action:

In response to these violations, the USFDA has demanded a detailed remediation plan from Zydus.

The plan must outline specific timelines for addressing the identified contamination hazards.

Additionally, the regulator has advised the company to seek external consulting expertise to ensure compliance with good manufacturing practices (GMP).

Potential Consequences of Non-Compliance:

If Zydus fails to address these issues promptly and effectively, the USFDA could take significant action.

This could include withholding approval for new applications, suspending existing approvals, or even imposing import restrictions.

The Importance of GMP Compliance:

The USFDA’s warning letter underscores the critical importance of adhering to GMP standards in the pharmaceutical industry.

These standards are designed to ensure the safety, quality, and efficacy of drug products.

Failure to comply with GMP can have serious consequences for both patients and manufacturers.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news